Home/Filings/4/0000950170-25-102537
4//SEC Filing

EDELMAN JOSEPH 4

Accession 0000950170-25-102537

CIK 0001814114other

Filed

Aug 4, 8:00 PM ET

Accepted

Aug 5, 10:46 AM ET

Size

11.8 KB

Accession

0000950170-25-102537

Insider Transaction Report

Form 4
Period: 2025-08-01
Transactions
  • Purchase

    Common Stock

    2025-08-01$2.75/sh+700,000$1,925,0005,292,556 total(indirect: See Footnote)
  • Purchase

    Pre-funded Warrants (right to buy)

    2025-08-01$2.75/sh+1,500,000$4,124,8501,500,000 total(indirect: See footnote)
    Exercise: $0.00Common Stock (1,500,000 underlying)
Transactions
  • Purchase

    Pre-funded Warrants (right to buy)

    2025-08-01$2.75/sh+1,500,000$4,124,8501,500,000 total(indirect: See footnote)
    Exercise: $0.00Common Stock (1,500,000 underlying)
  • Purchase

    Common Stock

    2025-08-01$2.75/sh+700,000$1,925,0005,292,556 total(indirect: See Footnote)
Transactions
  • Purchase

    Pre-funded Warrants (right to buy)

    2025-08-01$2.75/sh+1,500,000$4,124,8501,500,000 total(indirect: See footnote)
    Exercise: $0.00Common Stock (1,500,000 underlying)
  • Purchase

    Common Stock

    2025-08-01$2.75/sh+700,000$1,925,0005,292,556 total(indirect: See Footnote)
Footnotes (4)
  • [F1]Represents the purchase price for each share of Common Stock purchased by the Reporting Person in the Issuer's registered public offering that closed on August 1, 2025.
  • [F2]The securities are directly held by Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of the Master Fund. Joseph Edelman ("Mr. Edelman") serves as the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of their indirect pecuniary interest therein, and this report shall not be deemed an admission that the Advisor or Mr. Edelman are beneficial owner of such securities for purposes of Section 16 or for any other purposes.
  • [F3]The pre-funded warrants are immediately exercisable and will expire on the date they are exercised in full, subject to the Beneficial Ownership Limitation.
  • [F4]Represents the purchase price for each pre-funded warrant purchased by the Reporting Person in the Issuer's registered public offering that closed on August 1, 2025.

Documents

1 file

Issuer

Orchestra BioMed Holdings, Inc.

CIK 0001814114

Entity typeother

Related Parties

1
  • filerCIK 0001164426

Filing Metadata

Form type
4
Filed
Aug 4, 8:00 PM ET
Accepted
Aug 5, 10:46 AM ET
Size
11.8 KB